Research Paper Volume 11, Issue 14 pp 5058—5069

Figure 5. MiR-548d-3p inhibits osteosarcoma. (A) MG63 cell growth was measured with an MTT assay after treatment with control miRNA, 10 μM etoposide combined with control miRNA, or 10 μM etoposide combined with miR-548d-3p mimics. The results represent the mean±SD of three independent experiments. **P < 0.05 vs. control, ##P < 0.05 vs. etoposide. (B, C) MG63 cells were treated with control miRNA, 10 μM etoposide combined with control miRNA, or 10 μM etoposide combined with miR-548d-3p mimics. The protein and mRNA levels of KRAS were then measured by Western blotting and real-time PCR, respectively. **P < 0.05 vs. control, ##P < 0.05 vs. etoposide. The results represent the mean±SD of three independent experiments. (D) The migration of osteosarcoma cells to the lungs in mice treated with miR-548d-3p agomirs or control miRNA. The results represent the mean±SD. **P < 0.05 vs. control. (E) Immunohistochemical staining revealed the expression of KRAS in osteosarcoma in the control group and the miR-548d-3p overexpression group. (F, G) The protein and mRNA levels of KRAS were measured in MG63 cells by Western blotting and real-time PCR, respectively. The results represent the mean±SD of three independent experiments. **P < 0.05 vs. control. (H) The mechanism proposed in this article.